What is Ser-Ap-Es
HydrochlorothiazideThe Generic name of this drug
Treatment SummaryHydrochlorothiazide is a medication used to treat swelling and high blood pressure. It is the most commonly prescribed thiazide diuretic, but its use is declining in favor of drugs such as angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. It was approved by the FDA in 1959 and is available in combination with other drugs.
Esidrixis the brand name
Ser-Ap-Es Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Esidrix
Hydrochlorothiazide
1959
2181
Approved as Treatment by the FDA
Hydrochlorothiazide, also called Esidrix, is approved by the FDA for 22 uses including Stroke and Edema .Stroke
Used to treat Cerebrovascular Accident in combination with Losartan
Edema
Helps manage Premenstrual tension with edema
inadequate response to other therapeutic measures
Used to treat inadequate response to other therapeutic measures in combination with Spironolactone
Therapeutic procedure
Used to treat inadequate response to treatment in combination with Spironolactone
Hypertensive disease
Used to treat High Blood Pressure (Hypertension) in combination with Losartan
inadequate control of blood pressure with monotherapy
Used to treat inadequate control of blood pressure with monotherapy in combination with Aliskiren
Nephrotic Syndrome
Used to treat Nephrotic Syndrome in combination with Spironolactone
restriction of fluid and sodium
Used to treat restriction of fluid and sodium in combination with Spironolactone
blood pressure inadequately controlled with monotherapy
Used to treat blood pressure inadequately controlled with monotherapy in combination with Irbesartan
Congestive Heart Failure
Used to treat Congestive Heart Failure (CHF) in combination with Spironolactone
Left Ventricular Hypertrophy
Used to treat Left Ventricular Hypertrophy in combination with Losartan
Antihypertensive Treatment
Used to treat Antihypertensive Treatment in combination with Eprosartan
Cirrhosis
Used to treat Cirrhosis of the Liver in combination with Spironolactone
Hypertensive disease
Used to treat Hypertension, Essential Hypertension in combination with Spironolactone
Diuretics
Used to treat Hypokalemia caused by diuretics in combination with Amiloride
Antepartum magnesium sulfate prophylaxis
Helps manage prophylaxis of preeclampsia
calcium channel blockers
Used to treat calcium channel blockers in combination with Eprosartan
Sodium retention
Used to treat Sodium retention in combination with Spironolactone
Swollen feet or ankles
Used to treat Edema in combination with Triamterene
hypokalemia with solo treatment
Used to treat hypokalemia with solo treatment in combination with Triamterene
Ascites
Used to treat Ascites in combination with Spironolactone
Bedrest
Used to treat Bedrest in combination with Spironolactone
Effectiveness
How Ser-Ap-Es Affects PatientsHydrochlorothiazide helps the body get rid of more water through urine. The amount of hydrochlorothiazide taken will vary from person to person, but is usually between 25-100mg. People with weakened kidney or liver function should be especially careful when taking this drug.
How Ser-Ap-Es works in the bodyHydrochlorothiazide works by preventing the reabsorption of sodium and chloride, which causes water to be excreted from the body. This drug is transported from the blood into the cells lining the distal convoluted tubule in the kidneys, and then sent to the lumen of the tubule. Normally, sodium is reabsorbed into these cells and then pumped out into the bloodstream, causing a concentration gradient that encourages water to be reabsorbed. However, by blocking this reabsorption process, hydrochlorothiazide decreases the concentration gradient and reduces the amount of water that is reabsorbed by the body.
When to interrupt dosage
The suggested dosage of Ser-Ap-Es is contingent upon the identified condition, like Antepartum magnesium sulfate prevention, inadequately regulated blood pressure with single treatment and antihypertensives. The measure of dosage fluctuates in accordance with the technique of administration (e.g. Tablet, coated - Oral or Oral) recorded in the table beneath.Condition
Dosage
Administration
calcium channel blockers
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Therapeutic procedure
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Nephrolithiasis
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Hypertensive disease
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Swollen feet or ankles
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Hypertensive disease
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Bedrest
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
prophylaxis of calcium nephrolithiasis
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Antepartum magnesium sulfate prophylaxis
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Edema
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
hypokalemia with solo treatment
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Diuretics
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
inadequate response to other therapeutic measures
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
blood pressure inadequately controlled with monotherapy
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Therapeutic procedure
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Ascites
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
inadequate control of blood pressure with monotherapy
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
antihypertensives
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Diabetes Insipidus
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Nephrotic Syndrome
25.0 mg, , 12.5 mg, 50.0 mg, 15.0 mg, 6.25 mg, 2.5 mg/mg, 5.0 mg/mg, 100.0 mg, 0.125 mg, 0.25 mg, 30.0 mg, 0.0125 mg
Tablet, coated - Oral, Oral, , Tablet, Tablet - Oral, Tablet, film coated - Oral, Capsule, gelatin coated - Oral, Tablet, film coated, Capsule, Tablet, coated, Capsule - Oral, Capsule, gelatin coated
Warnings
Ser-Ap-Es ContraindicationsCondition
Risk Level
Notes
Toxoplasma Infections
Do Not Combine
Anuria
Do Not Combine
Common Ser-Ap-Es Drug Interactions
Drug Name
Risk Level
Description
Amifostine
Major
Hydrochlorothiazide may increase the hypotensive activities of Amifostine.
Cyclopentamine
Major
The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclopentamine.
Dofetilide
Major
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dofetilide.
Fenofibrate
Major
The therapeutic efficacy of Fenofibrate can be decreased when used in combination with Hydrochlorothiazide.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Hydroxyzine.
Ser-Ap-Es Toxicity & Overdose RiskThe lowest toxic dose of hydrochlorothiazide in mice and rats has been found to be greater than 10g/kg. Those who overdose on the drug may experience low levels of potassium, chloride, and sodium in the blood. To treat these symptoms, supportive care including fluids and electrolytes is recommended, as well as vasopressors to treat hypotension and oxygen for respiratory impairment.
Ser-Ap-Es Novel Uses: Which Conditions Have a Clinical Trial Featuring Ser-Ap-Es?
158 active clinical trials are currently examining the potential of Ser-Ap-Es in providing relief from Cirrhosis, Edema and Congestive Heart Failure.Condition
Clinical Trials
Trial Phases
Stroke
14 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Cirrhosis
59 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1
Swollen feet or ankles
45 Actively Recruiting
Phase 1, Phase 2, Phase 4, Not Applicable, Early Phase 1, Phase 3
Nephrotic Syndrome
13 Actively Recruiting
Phase 2, Not Applicable, Phase 3
inadequate control of blood pressure with monotherapy
0 Actively Recruiting
antihypertensives
0 Actively Recruiting
Bedrest
0 Actively Recruiting
Ascites
12 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 1
Hypertensive disease
22 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4
Antepartum magnesium sulfate prophylaxis
13 Actively Recruiting
Phase 1, Not Applicable, Phase 3, Early Phase 1
blood pressure inadequately controlled with monotherapy
0 Actively Recruiting
Hypertensive disease
3 Actively Recruiting
Phase 1, Not Applicable
Left Ventricular Hypertrophy
3 Actively Recruiting
Not Applicable, Phase 4
restriction of fluid and sodium
0 Actively Recruiting
Congestive Heart Failure
24 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Diabetes Insipidus
2 Actively Recruiting
Phase 1, Phase 2
Edema
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Sodium retention
0 Actively Recruiting
Ser-Ap-Es Reviews: What are patients saying about Ser-Ap-Es?
5Patient Review
1/29/2019 This drug has been the most effective in lowering my blood pressure to a normal level. I have tried many different drugs, but none of them have been as successful as this one.